Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06744296 · ClinicalTrials.gov registry record

Measurable Residual Disease Detection Using Tumor-Informed ctDNA Surveillance After Curative-Intent Treatment in HPV-Independent Squamous Cell Carcinoma of the Head and Neck

A clinical trial of Squamous Cell Carcinoma of Head and Neck, sponsored by Massachusetts Eye and Ear Infirmary.

Recruiting
Registry status
75
Enrollment target
1
Study location

NCT06744296: Recruiting study of Squamous Cell Carcinoma of Head and Neck, sponsored by Massachusetts Eye and Ear Infirmary.

NCT06744296 is a study of Squamous Cell Carcinoma of Head and Neck that is actively recruiting participants, run by Massachusetts Eye and Ear Infirmary. The registered enrollment target is 75 participants, below the 168-participant average among 37 other Squamous Cell Carcinoma of Head and Neck trials with a reported enrollment target (55% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06744296, a study of Squamous Cell Carcinoma of Head and Neck, is actively recruiting participants, sponsored by Massachusetts Eye and Ear Infirmary.

RECRUITING
Registry status
75 participants
Enrollment target
1
Study location

Study Summary

This study will test the ability of a personalized blood test to determine which head and neck cancer patients will have a recurrence after treatment.

Primary Outcome

2-year disease-free survival (DFS) in patients with detectable vs no detectable ctDNA two weeks after treatment completion

Interventions

  • OTHER Blood Draws and Tissue Sample(s)

Study Locations (1)

Massachusetts

  • Massachusetts Eye and Ear - Boston

Trial Details

FieldValue
Enrollment Target 75 participants
Start Date 2025-02-03
Est. Completion 2029-01-06

What NCT06744296 shows while recruiting

NCT06744296 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 168-participant average among 37 other Squamous Cell Carcinoma of Head and Neck trials with a reported enrollment target (55% lower).

The record links to 1 condition, with Squamous Cell Carcinoma of Head and Neck appearing as the primary indexed condition, and to 1 intervention - of which Blood Draws and Tissue Sample(s) is the first listed.

NCT06744296 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06744296 about?

NCT06744296 is a clinical study titled "Measurable Residual Disease Detection Using Tumor-Informed ctDNA Surveillance After Curative-Intent Treatment in HPV-Independent Squamous Cell Carcinoma of the Head and Neck". This study will test the ability of a personalized blood test to determine which head and neck cancer patients will have a recurrence after treatment.

What is the current status of trial NCT06744296?

This trial is currently recruiting. The enrollment target is 75 participants. The study started on 2025-02-03. Estimated completion is 2029-01-06.

What conditions does trial NCT06744296 study?

This clinical trial studies the following conditions: Squamous Cell Carcinoma of Head and Neck.

What interventions are being tested in trial NCT06744296?

The interventions under investigation include: Blood Draws and Tissue Sample(s) (OTHER).

Who is sponsoring clinical trial NCT06744296?

This trial is sponsored by Massachusetts Eye and Ear Infirmary, which has 73 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06744296 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Squamous Cell Carcinoma of Head and Neck

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06744296's enrollment target sits among peer trials

75 18th of 37 higher than 20 of 37 other Squamous Cell Carcinoma of Head and Neck trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Squamous Cell Carcinoma of Head and Neck trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01535430 · 75 participants

    Assessment of Eloquent Function in Brain Tumor Patients

  • NCT01542879 · 75 participants · Phase 1

    Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer

  • NCT02232191 · 75 participants · Phase 2

    Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients

  • NCT02754544 · 75 participants · NA

    Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06744296, the US trial registry maintained by the National Library of Medicine. NCT06744296 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.